HIV-associated Pneumocystis pneumonia - PubMed (original) (raw)
Review
HIV-associated Pneumocystis pneumonia
Laurence Huang et al. Proc Am Thorac Soc. 2011 Jun.
Abstract
During the past 30 years, major advances have been made in our understanding of HIV/AIDS and Pneumocystis pneumonia (PCP), but significant gaps remain. Pneumocystis is classified as a fungus and is host-species specific, but an understanding of its reservoir, mode of transmission, and pathogenesis is incomplete. PCP remains a frequent AIDS-defining diagnosis and is a frequent opportunistic pneumonia in the United States and in Europe, but comparable epidemiologic data from other areas of the world that are burdened with HIV/AIDS are limited. Pneumocystis cannot be cultured, and bronchoscopy with bronchoalveolar lavage is the gold standard procedure to diagnose PCP, but noninvasive diagnostic tests and biomarkers show promise that must be validated. Trimethoprim-sulfamethoxazole is the recommended first-line treatment and prophylaxis regimen, but putative trimethoprim-sulfamethoxazole drug resistance is an emerging concern. The International HIV-associated Opportunistic Pneumonias (IHOP) study was established to address these knowledge gaps. This review describes recent advances in the pathogenesis, epidemiology, diagnosis, and management of HIV-associated PCP and ongoing areas of clinical and translational research that are part of the IHOP study and the Longitudinal Studies of HIV-associated Lung Infections and Complications (Lung HIV).
Figures
Figure 1.
Annual number of microscopically confirmed cases of Pneumocystis pneumonia (PCP) diagnosed at San Francisco General Hospital, 1990–2009. ART = antiretroviral therapy.
Figure 2.
Chest radiograph demonstrating the characteristic bilateral, symmetric granular opacities in an HIV-infected patient with Pneumocystis pneumonia (courtesy of L. Huang, used with permission).
Figure 3.
Chest high-resolution computed tomograph demonstrating the characteristic ground glass opacities in an HIV-infected patient with Pneumocystis pneumonia who had a normal chest radiograph (courtesy of L. Huang, used with permission).
Similar articles
- Dihydropteroate synthase (DHPS) gene mutation study in HIV-Infected Indian patients with Pneumocystis jirovecii pneumonia.
Tyagi AK, Mirdha BR, Luthra K, Guleria R, Mohan A, Singh UB, Samantaray JC, Dar L, Iyer VK, Chaudhry R. Tyagi AK, et al. J Infect Dev Ctries. 2010 Nov 24;4(11):761-6. doi: 10.3855/jidc.914. J Infect Dev Ctries. 2010. PMID: 21252456 - New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.
Kovacs JA, Gill VJ, Meshnick S, Masur H. Kovacs JA, et al. JAMA. 2001 Nov 21;286(19):2450-60. doi: 10.1001/jama.286.19.2450. JAMA. 2001. PMID: 11712941 - A background and critical analysis of the treatment of pneumocystis carinii pneumonia (PCP) in HIV/AIDS.
Mitchell B. Mitchell B. Aust Nurs J. 2007 Apr;14(9):20-3. Aust Nurs J. 2007. PMID: 17441498 Review. No abstract available. - Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.
Huang YS, Yang JJ, Lee NY, Chen GJ, Ko WC, Sun HY, Hung CC. Huang YS, et al. Expert Rev Anti Infect Ther. 2017 Sep;15(9):873-892. doi: 10.1080/14787210.2017.1364991. Epub 2017 Aug 21. Expert Rev Anti Infect Ther. 2017. PMID: 28782390 Review. - High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy.
Ponce CA, Chabé M, George C, Cárdenas A, Durán L, Guerrero J, Bustamante R, Matos O, Huang L, Miller RF, Vargas SL. Ponce CA, et al. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01290-16. doi: 10.1128/AAC.01290-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27855071 Free PMC article.
Cited by
- Pneumocystis jirovecii Pneumonia and HIV-Associated Nephropathy in Acute HIV Infection.
Hedayatpour S, Albonijim A, Avila J. Hedayatpour S, et al. Cureus. 2024 Sep 11;16(9):e69189. doi: 10.7759/cureus.69189. eCollection 2024 Sep. Cureus. 2024. PMID: 39398652 Free PMC article. - Metabolic modulation: Pneumocystis phosphoglucomutase is a target influencing host recognition.
Kottom TJ, Carmona EM, Lepenies B, Limper AH. Kottom TJ, et al. Cell Surf. 2024 Mar 25;11:100123. doi: 10.1016/j.tcsw.2024.100123. eCollection 2024 Jun. Cell Surf. 2024. PMID: 39022598 Free PMC article. Review. - Pulmonary symptoms associated with heavy alcohol consumption among people living with HIV: an analysis of the NHANES 1999-2010.
New-Aaron M, Kang M, Yeligar SM. New-Aaron M, et al. Alcohol Alcohol. 2024 Mar 16;59(3):agae021. doi: 10.1093/alcalc/agae021. Alcohol Alcohol. 2024. PMID: 38581190 - Pneumocystis jirovecii pneumonia in people living with HIV: a review.
McDonald EG, Afshar A, Assiri B, Boyles T, Hsu JM, Khuong N, Prosty C, So M, Sohani ZN, Butler-Laporte G, Lee TC. McDonald EG, et al. Clin Microbiol Rev. 2024 Mar 14;37(1):e0010122. doi: 10.1128/cmr.00101-22. Epub 2024 Jan 18. Clin Microbiol Rev. 2024. PMID: 38235979 Review. - Molecular Analysis of Dihydropteroate Synthase Gene Mutations in Pneumocystis jirovecii Isolates among Bulgarian Patients with Pneumocystis Pneumonia.
Tsvetkova N, Harizanov R, Rainova I, Ivanova A, Yancheva-Petrova N. Tsvetkova N, et al. Int J Mol Sci. 2023 Nov 29;24(23):16927. doi: 10.3390/ijms242316927. Int J Mol Sci. 2023. PMID: 38069248 Free PMC article.
References
- Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA 2009;301:2578–2585. - PubMed
- Vargas SL, Hughes WT, Santolaya ME, Ulloa AV, Ponce CA, Cabrera CE, Cumsille F, Gigliotti F. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001;32:855–861. - PubMed
- Meuwissen JH. Infections with Pneumocystis carinii. Natl Cancer Inst Monogr 1976;43:133–136. - PubMed
- Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978;61:35–41. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HL090335-02S1/HL/NHLBI NIH HHS/United States
- K23 HL094141/HL/NHLBI NIH HHS/United States
- HL087713/HL/NHLBI NIH HHS/United States
- K24 HL087713/HL/NHLBI NIH HHS/United States
- R01 HL090335/HL/NHLBI NIH HHS/United States
- HL090335/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous